122 related articles for article (PubMed ID: 23637199)
21. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
Knudtson M; Tiso S; Phillips S
Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
[TBL] [Abstract][Full Text] [Related]
22. Only one-third of girls receive HPV vaccine.
Hum Vaccin; 2010 Jul; 6(7):525. PubMed ID: 20622519
[No Abstract] [Full Text] [Related]
23. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.
Laprise JF; Markowitz LE; Chesson HW; Drolet M; Brisson M
J Infect Dis; 2016 Sep; 214(5):685-8. PubMed ID: 27234416
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with completion of the human papillomavirus vaccine series.
Neubrand TP; Breitkopf CR; Rupp R; Breitkopf D; Rosenthal SL
Clin Pediatr (Phila); 2009 Nov; 48(9):966-9. PubMed ID: 19483128
[No Abstract] [Full Text] [Related]
25. HPV vaccine recommendations.
Committee on Infectious Diseases
Pediatrics; 2012 Mar; 129(3):602-5. PubMed ID: 22371460
[TBL] [Abstract][Full Text] [Related]
26. HPV vaccination in Italy: perspectives after 1-year experience.
Icardi G
J Prev Med Hyg; 2008 Dec; 49(4):125-8. PubMed ID: 19350958
[No Abstract] [Full Text] [Related]
27. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
[TBL] [Abstract][Full Text] [Related]
28. A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health.
Francis SA; Battle-Fisher M; Liverpool J; Hipple L; Mosavel M; Soogun S; Mofammere N
Vaccine; 2011 Nov; 29(47):8760-5. PubMed ID: 21855591
[TBL] [Abstract][Full Text] [Related]
29. Sexually active women may also benefit from HPV vaccine.
Cooper C
RN; 2006 Dec; 69(12):12. PubMed ID: 17225553
[No Abstract] [Full Text] [Related]
30. HPV vaccine and males: issues and challenges.
Zimet GD; Rosenthal SL
Gynecol Oncol; 2010 May; 117(2 Suppl):S26-31. PubMed ID: 20129653
[TBL] [Abstract][Full Text] [Related]
31. The two faces of human papillomavirus.
Frazer IH
Gynecol Oncol; 2010 May; 117(2 Suppl):S4. PubMed ID: 20110119
[No Abstract] [Full Text] [Related]
32. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
[TBL] [Abstract][Full Text] [Related]
33. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
35. Call for HPV vaccine reduction.
J Fam Health Care; 2014 Jun; 24(4):6. PubMed ID: 25112037
[No Abstract] [Full Text] [Related]
36. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination.
Smolen KK; Gelinas L; Franzen L; Dobson S; Dawar M; Ogilvie G; Krajden M; Fortuno ES; Kollmann TR
Vaccine; 2012 May; 30(24):3572-9. PubMed ID: 22469863
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus vaccine: an updated position statement of the Society for Adolescent Health and Medicine.
Friedman L; Bell DL; Kahn JA; Marcell AV; Middleman AB; Rosenthal SL; Zimet GD
J Adolesc Health; 2011 Feb; 48(2):215-6. PubMed ID: 21257124
[No Abstract] [Full Text] [Related]
38. [The first HPV vaccine is now available].
Kjaer SK; Olesen F; Toftager-Larsen K; Sand C; Strauss GI; Hoffmann TU; Ottesen BS
Ugeskr Laeger; 2006 Oct; 168(44):3827-8. PubMed ID: 17118245
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
[TBL] [Abstract][Full Text] [Related]
40. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
